Goldman Sachs Maintains Buy on Johnson & Johnson

Goldman Sachs is out with its report today on Johnson & Johnson JNJ, maintaining Buy. In a note to clients, Goldman Sachs writes, "We continue to see JNJ as the best underappreciated new product story in Pharma, with the only accelerating earnings trajectory over the next three years across the global sector. Fueled by an emerging pipeline in Pharma, stabilization in MD&D and bottoming out in Consumer, we see acceleration to 9%-10% EPS growth over the next three years from the 2-3% over the last two years." At the time of posting, shares of JNJ were trading pre-market at $66.00, down 0.24% from Wednesday's close.